SHIN-ETSU-CHEMICAL
Shin-Etsu Chemical Co., Ltd., (Head Office: Tokyo; President: Yasuhiko Saitoh) has developed a new series of products, the KCP Series, a new vulcanization type of one-component liquid silicone rubber.
One-component liquid silicone rubber cures at room temperature by reacting to the atmospheric humidity. After curing, because it has superior combined characteristics, including heat resistance, cold resistance, weather resistance and outstanding electrical properties, it is used as adhesive/sealing materials and coating materials in such products as component parts for electric vehicles (EV), semiconductors, and electric/electronics. Furthermore, because it cures at room temperature, it is not necessary to have a heating furnace and ultraviolet (UV) irradiation equipment. Accordingly, these new products will contribute to reducing environmental impact.
The KCP Series of products are a type that releases cyclopentanone*1 at the time of the curing reaction. This new product series will meet the expectations of our customers with its improved vulcanization characteristics, higher level of safety and excellent handleability compared to existing products.*2 The main characteristics of these new products are as follows:
1: The vulcanization speed is fast and also the adhesion develops quickly, and thus work efficiency improves. The tack-free time*3 of KCP-102 is 3 minutes, ½ of the time of the existing KE-4898-W*4 product.
2: The odor that is generated at the time of curing is lower, and has a higher level of safety.
3: Because the ignition temperature is high, at more than 70 ℃, the handling time and effort needed during the time of transport and storage can be reduced.
4: It exhibits good adhesion with various resins and also there are almost no corrosive effects on metals.*5
There are 3 products lined up in the KCP Series according to their viscosity index: KCP-100 (low viscosity), KCP-101 (mid-viscosity) and KCP-102 (paste type). All of them are tube-type, and one can work simply by pushing the contents out from the tube-type container. Going forward, Shin-Etsu Chemical will continue to strive to meet the requests of our customers and develop products that have various added functions as we work to expand the line-up of our products.
Shin-Etsu Chemical will continue to endeavor to enhance our ability to contribute to the solution of various social and customer issues by developing and supplying advanced functional silicone products through making full use of the technological power and knowhow that Shin-Etsu has nurtured up to now, as we work to further contribute to the realization of the sustainability of society.
Footnotes:
*1 Cyclopentanone is an organic compound represented by the chemical formula (CH2 )4 CO. It is one of the cyclic ketones and is a volatile colorless liquid.
*2 Existing products include types of acetic acid, oxime, alcohol and acetone, and each have their own characteristics.
*3 It is the time that it takes until when one touches the surface, it will not stick to one’s finger.
*4 Curing Condition: 23℃/50%Relative Humidity
*5 Metal substrates should be tested prior to use with this product to insure performance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220329006080/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom